This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SF 383 prohibits PBMs from limiting patient choice of pharmacy, unfairly excluding pharmacies from networks, and forces them to reimburse pharmacies no less than what they pay affiliated pharmacies for the same drug.
As lawmakers in Lansing debate health care legislation, new evidence reveals a staggering—and deeply troubling—reality: big, tax-exempt hospitals in the state are marking up the price of prescription medicines by nearly $10 billion a year. The federal 340B program is running unchecked with limited transparency and accountability, and comprehensive federal reform is needed to stop abuse of the program.
Retail pharmacies are undergoing a meaningful transformation into accessible, community-based health care hubs by expanding clinical services, embracing value-based care, and addressing gaps in access, technology, and reimbursement.
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A nephropathy (IgAN), a chronic kidney disease. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab. The data was presented at the European Renal Association Congress on 6 June 2025 […] The post Takeda presents positive results from trial of chronic kidney disease treatment appeared first on Pharmafi
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Direct-to-consumer drug sales may undermine patient care and threaten independent pharmacies by reducing access to personalized, comprehensive medication management.
The United States is the epicenter of groundbreaking biopharmaceutical research, and maintaining this leadership requires investment in the future scientific workforce. This year marks the 60th year that the PhRMA Foundation has helped build and train this workforce. A 501(c)(3) nonprofit, the Foundation provides grants and fellowships to graduate students, postdoctoral trainees and new faculty members conducting novel research, setting the stage for tomorrow’s biomedical breakthroughs tha
100
100
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
The United States is the epicenter of groundbreaking biopharmaceutical research, and maintaining this leadership requires investment in the future scientific workforce. This year marks the 60th year that the PhRMA Foundation has helped build and train this workforce. A 501(c)(3) nonprofit, the Foundation provides grants and fellowships to graduate students, postdoctoral trainees and new faculty members conducting novel research, setting the stage for tomorrow’s biomedical breakthroughs tha
Amy Duong, PharmD, BCACP, explains pharmacists' critical role in promoting chronic inflammatory demyelinating neuropathy (CIDP) treatment adherence and staying informed about new therapeutic developments.
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
At the Total Pharmacy Solutions Summit Spring 2025 event, diagnostics experts Jenna Anderson and Amanda Wiley explored community pharmacists’ role in at-home testing.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
When House Republicans voted in the wee hours of the morning of May 22 to cut approximately $700 billion from Medicaid , they moved one step closer to rendering dangerously vulnerable the millions of Medicaid recipients struggling with mental illness and substance use disorder. Medicaid, which covers more than 72 million Americans, is the single largest payer of behavioral health services , which includes mental health and substance use disorder treatment.
Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59, following earlier approvals for older populations.
By Max Kopp Diabetes care is entering a new era—yet even in 2025, continuous glucose monitors (CGMs) remain out of reach for millions. Despite a decade of innovation, current CGMs often fail to meet the needs of everyday people with type 2 diabetes, particularly those in under-resourced or underserved communities. High costs, skin invasiveness, and insurance limitations act as real barriers, not just for adoption, but for long-term engagement.
The U.S. Food and Drug Administration (FDA) has approved Widaplik, a new triple combination medication designed to treat high blood pressure in adults. Widaplik is the first single pill containing three different drugs approved as an initial treatment for hypertension. It’s a huge win for people who would otherwise likely need several different prescriptions to optimize their cardiovascular health.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Researchers developed, pilot-tested, and evaluated the feasibility of a telehealth electronic application that simulated pharmacists’ prescribing of contraceptives to adolescents and young adults.
The staff of two world-class laboratories at the Centers for Disease Control and Prevention that were slated to be closed in a round of cuts announced in April have been informed that their terminations have been canceled. The CDC’s sexually transmitted disease laboratory and its viral hepatitis laboratory were targets of layoffs initiated by the U.S.
In two phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
Europe’s comparatively cautious approach to food additives is the envy of health secretary Robert F. Kennedy Jr. and the Make America Healthy Again movement. A Texas bill now before Gov. Greg Abbott aims to help close the gap by slapping warning labels on foods that contain any of 44 additives and dyes. Abbott has not said whether he intends to sign Senate Bill 25 into law.
Innovative strategies are essential to recruit pharmacy students and transform practices, ensuring equitable access to pharmacy services in underserved areas.
As regulator prepares to approve lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’ A drug with the potential to “end the HIV pandemic” will launch in the US this week – as a new study reveals it could be sold for 1,000 times less than its possible price tag. Lenacapavir, given as a twice-yearly injection, can prevent someone from being infected with HIV, according to clinical trial results.
Amina Abubakar, PharmD, AAHIVP, joined Drug Topics to discuss her career journey as an independent pharmacy owner and the ways in which she’s been able to grow her business.
In December 2023, a groundbreaking announcement grabbed headlines : After years of anticipation, the Food and Drug Administration approved the first gene therapies for treating sickle cell disease, offering hope of eliminating life-altering symptoms. News at the time also featured the treatment’s prohibitive cost — between $2 and $3 million per person.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, co-chair of the 2025 Oncology Pharmacists Connect (OPC) meeting, discusses what makes the event unique, highlights key sessions, and shares her excitement for the educational and networking opportunities.
Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals.
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
We recently went viral. Well, not exactly us — but people like us. We are participants in the Yale LISTEN Study , a patient-centered study to better understand long Covid and the adverse effects some patients have experienced post Covid-vaccination. We are members of the post-vaccination cohort, a group that includes more than 250 patients.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content